Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like A*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000018	ACADIA Pharmaceuticals Inc.	12/31/2019	63090034030	NUPLAZID Oral Capsule 34 MG 30	12/30/2019	155.00	3341.00	08/27/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000018	ACADIA Pharmaceuticals Inc.	12/31/2019	63090010030	NUPLAZID Oral Tablet 10 MG 30	12/30/2019	155.00	3341.00	03/23/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000021	Acorda Therapeutics, Inc.	12/31/2019	10144042760	AMPYRA (dalfampridine) Extended Release 10mg Tablets / 60 Tablet Bottles	10/01/2019	242.27	2934.14	None	Innovator Multiple Source Drug	98877	None	AMPYRA® has not been reformulated, but AMPYRA® is the manufacturer's primary source of revenue while revenue from a more recently-approved product, INBRIJA™, increases.	None	AMPYRA® has not been reformulated, but AMPYRA® is the manufacturer's primary source of revenue while revenue from a more recently-approved product, INBRIJA™, increases.	None	None	None	None	None	None	None	None	None	None	None	Regarding the inquiry relating to acquisition and patent: Regarding Patent & Patent Expiration: Acorda has filed a request with the FDA to delist the AMPYRA® patents from the Orange Book (Approved Drug Products with Therapeutic Equivalents). There are currently multiple generics on the market. Regarding Acquisition: Acorda did not acquire AMPYRA® within the previous five year period.
Rx0000157	Acrotech Biopharma LLC	06/30/2019	68152010809	BELEODAQ® (belinostat)for Injection - 500mg single-dose vial	04/01/2019	28.28	1913.58	10/27/2027	Single Source Drug	8569	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	1885.30	None	2014	1500.00	None	None
Rx0000157	Acrotech Biopharma LLC	09/30/2019	68152010809	BELEODAQ® (belinostat)for Injection - 500mg single-dose vial	07/15/2019	28.70	1942.28	10/27/2027	Single Source Drug	9394	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	1885.30	None	2014	1500.00	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2019	68152010809	BELEODAQ® (belinostat)for Injection - 500mg single-dose vial	10/01/2019	29.14	1971.42	10/27/2027	Single Source Drug	8569	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	1885.30	1776.30	2014	1500.00	None	None
Rx0000157	Acrotech Biopharma LLC	06/30/2019	48818000101	FOLOTYN® (pralatrexate injection) 20mg, 20mg/mL, 1ml Vial	04/01/2019	81.64	5524.33	05/31/2025	Single Source Drug	3948	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	5442.69	None	2009	3125.00	None	None
Rx0000157	Acrotech Biopharma LLC	09/30/2019	48818000101	FOLOTYN® (pralatrexate injection) 20mg, 20mg/mL, 1ml Vial	07/15/2019	82.87	5607.20	05/31/2025	Single Source Drug	4273	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	5442.69	None	2009	3125.00	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2019	48818000101	FOLOTYN® (pralatrexate injection) 20mg, 20mg/mL, 1ml Vial	10/01/2019	106.53	5713.73	05/31/2025	Single Source Drug	3948	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	5442.69	5047.97	2009	3125.00	None	None
Rx0000157	Acrotech Biopharma LLC	06/30/2019	48818000102	FOLOTYN® (pralatrexate injection) 40mg, 20mg/mL, 2ml Vial	04/01/2019	163.28	11048.66	05/31/2025	Single Source Drug	2516	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	10885.38	None	2009	6250.00	None	None
Rx0000157	Acrotech Biopharma LLC	09/30/2019	48818000102	FOLOTYN® (pralatrexate injection) 40mg, 20mg/mL, 2ml Vial	07/15/2019	165.74	11214.40	05/31/2025	Single Source Drug	2667	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	10885.38	None	2009	6250.00	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2019	48818000102	FOLOTYN® (pralatrexate injection) 40mg, 20mg/mL, 2ml Vial	10/01/2019	213.06	11427.46	05/31/2025	Single Source Drug	2516	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	10885.38	10095.94	2009	6250.00	None	None
Rx0000157	Acrotech Biopharma LLC	06/30/2019	20536032201	MARQIBO® (vinCRIStine sulfate LIPOSOME injection)	04/01/2019	214.41	14508.62	09/25/2020	Single Source Drug	558	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	14294.21	None	2013	9750.00	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2019	20536032201	MARQIBO® (vinCRIStine sulfate LIPOSOME injection)	10/01/2019	565.84	15074.46	09/25/2020	Single Source Drug	558	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	14294.21	13241.25	2013	9750.00	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431011001	JUXTAPID 10 MG CAPS, bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431012001	JUXTAPID 20 MG CAPS, bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431013001	JUXTAPID 30 MG CAPS, bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431014001	JUXTAPID 40 MG CAPS, bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431010501	JUXTAPID 5 MG CAPS - bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431016001	JUXTAPID 60 MG CAPS, bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431021001	MYALEPT 11.3MG VIAL - 1 vial	01/01/2019	419.06	4632.82	07/17/2027	Single Source Drug	None	1	None	1	None	1	01/12/2015	AstraZeneca	325000000	None	None	3493.00	None	2014	3493.00	None	The product was introduced to the market before it was acquired by Aegerion Pharmaceuticals which was later acquired by Amryt in 2019. The information provided in this report is the only information available to Amryt. Amryt has no knowledge of the WAC at introduction. Therefore the WAC Aegerion set after acquisition was used - 3493.00 as reported in MediSpan.
Rx0000151	Aerie Pharmaceuticals Inc.	09/30/2019	07072749725	Netarsudil ophthalmic solution 0.02%, 2.5mL bottle	09/23/2019	22.46	272.07	03/14/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Aerie Pharmaceuticals, Inc. developed Rhopressa. It is not an acquired product.
Rx0000085	Akorn Inc	03/31/2019	17478021515	Atropine Sulfate Ophth Sol 1% 10mg/mL,15mL, 1 Bottle	03/18/2019	31.09	114.83	None	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478030703	Azithromycin 1% Opth Soln 10mg, 2.5ml, 1 Bottle	03/18/2019	18.58	206.21	03/31/2019	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478050305	Dehydrated Alcohol 0.98mL/mL, 5ml, 10 Vials	03/18/2019	261.94	1295.00	None	Non-innovator Multiple Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478010610	Levofloxacin Ophth Solution 0.5%, 5ml, 1 Bottle/ EA	03/18/2019	52.39	114.89	None	Non-innovator Multiple Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478070102	lndocyanine Green 25mg,10ml / Amp, 6Amp	03/18/2019	111.23	683.59	None	Innovator Multiple Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478060930	Tafluprost Ophth Sol .0015%.3ml/.0045mg, .3mL-30 UD pk	03/18/2019	19.19	213.01	05/28/2029	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	04/01/2014	Merck	None	1	No comment	103.79	None	2014	103.79	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478004532	Tetracaine HCI Injection 1% lOmg/mL, 2ml, 25 Ampules	03/18/2019	994.47	1898.53	None	Non-innovator Multiple Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	76478000105	Timolol 0.25% Opth Solution 2.56mg/mL, 5ml, 1 Bottle	03/18/2019	11.51	127.76	None	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	76478000215	Timolol 0.5% Opth Solution 5.12mg/ml, 15ml, 1 Bottle	03/18/2019	36.74	407.89	None	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	76478000205	Timolol 0.5% Opth Solution 5.12mg/mL, 5ml, 1 Bottle	03/18/2019	12.71	141.07	None	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	76478000210	Timolol 0.50% Opth Solution 5.12mg/ml, 10ml, 1 Bottle	03/18/2019	24.41	271.01	None	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004230	Irbesartan 150mg Tablet 30ct	04/17/2019	63.91	75.00	None	Non-innovator Multiple Source Drug	12060	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004271	Irbesartan 150mg Tablet 500ct	04/17/2019	1068.80	1250.00	None	Non-innovator Multiple Source Drug	0	1	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004290	Irbesartan 150mg Tablet 90ct	04/17/2019	191.72	225.00	None	Non-innovator Multiple Source Drug	14040	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004330	Irbesartan 300mg Tablet 30ct	04/17/2019	76.15	90.00	None	Non-innovator Multiple Source Drug	3828	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004371	Irbesartan 300mg Tablet 500ct	04/17/2019	1269.20	1500.00	None	Non-innovator Multiple Source Drug	3984	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004390	Irbesartan 300mg Tablet 90ct	05/01/2019	228.46	270.00	None	Non-innovator Multiple Source Drug	23292	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004130	Irbesartan 75mg Tablet 30ct	04/17/2019	49.46	60.00	None	Non-innovator Multiple Source Drug	18744	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004190	Irbesartan 75mg Tablet 90ct	04/17/2019	148.38	180.00	None	Non-innovator Multiple Source Drug	0	1	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332005130	Irbesartan/Hydrochlorothiazide 150mg-12.5mg Tablet 30ct	04/08/2019	66.30	90.00	None	Non-innovator Multiple Source Drug	48	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332005190	Irbesartan/Hydrochlorothiazide 150mg-12.5mg Tablet 90ct	04/08/2019	201.30	270.00	None	Non-innovator Multiple Source Drug	936	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332005230	Irbesartan/Hydrochlorothiazide 300mg-12.5mg Tablet 30ct	04/08/2019	51.30	97.50	None	Non-innovator Multiple Source Drug	10356	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332005290	Irbesartan/Hydrochlorothiazide 300mg-12.5mg Tablet 90ct	04/08/2019	157.20	292.50	None	Non-innovator Multiple Source Drug	1860	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	09/30/2019	62332004930	Losartan Potassium/Hydrochlorothiazide 100mg-12.5mg Tablet 30ct	07/15/2019	36.03	41.25	None	Non-innovator Multiple Source Drug	6732	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	09/30/2019	62332004990	Losartan Potassium/Hydrochlorothiazide 100mg-12.5mg Tablet 90ct	07/15/2019	110.47	123.75	None	Non-innovator Multiple Source Drug	2028	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	09/30/2019	62332005030	Losartan Potassium/Hydrochlorothiazide 100mg-25mg Tablet 30ct	07/15/2019	36.03	41.25	None	Non-innovator Multiple Source Drug	17784	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	09/30/2019	62332005090	Losartan Potassium/Hydrochlorothiazide 100mg-25mg Tablet 90ct	07/15/2019	110.35	123.75	None	Non-innovator Multiple Source Drug	3456	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000039	Alkermes, Inc	03/31/2019	65757040103	ARISTADA 441 mg/ 1.6mL extended-release injectable suspension	02/22/2019	73.28	1294.73	10/26/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Aristada was developed in-house
Rx0000039	Alkermes, Inc	03/31/2019	65757040203	ARISTADA 662 mg/2.4mL extended-release injectable suspension	02/22/2019	110.01	1943.56	10/26/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Aristada was developed in-house
Rx0000039	Alkermes, Inc	03/31/2019	65757040303	ARISTADA 882 mg/3.2mL extended-release injectable suspension	02/22/2019	146.57	2589.46	10/26/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Aristada was developed in-house
Rx0000020	Allergan	03/31/2019	00430047801	ACTONEL-150 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	17.25	369.33	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430047802	ACTONEL-150 mg-3-CAPSULE,DELAYED RELEASE	01/01/2019	51.76	1108.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430047207	ACTONEL-35 mg-12-CAPSULE,DELAYED RELEASE	01/01/2019	47.78	1022.92	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430047203	ACTONEL-35 mg-4-CAPSULE,DELAYED RELEASE	01/01/2019	15.93	340.98	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430047115	ACTONEL-5 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	17.08	365.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023350730	ACUVAIL-0.45 %-30-DROPPERETTE, SINGLE-USE DROP DISPENSER	01/01/2019	14.87	318.31	03/07/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023932110	ALPHAGAN P-0.1 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	27.74	319.78	01/10/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023932115	ALPHAGAN P-0.1 %-15-CAPSULE,DELAYED RELEASE	01/01/2019	41.62	479.74	01/10/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023932105	ALPHAGAN P-0.1 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	13.88	159.96	01/10/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023917710	ALPHAGAN P-0.15 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	29.58	340.99	01/28/2022	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023917715	ALPHAGAN P-0.15 %-15-CAPSULE,DELAYED RELEASE	01/01/2019	44.38	511.53	01/28/2022	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023917705	ALPHAGAN P-0.15 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	14.80	170.54	01/28/2022	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544007660	ANDRODERM-2 mg/24 hour-60-CAPSULE,DELAYED RELEASE	01/01/2019	53.43	615.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023599060	ANDRODERM-2 mg/24 hour-60-PATCH, TRANSDERMAL 24 HOURS	01/01/2019	53.43	615.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544007730	ANDRODERM-4 mg/24 hour-30-CAPSULE,DELAYED RELEASE	01/01/2019	53.43	615.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023599230	ANDRODERM-4 mg/24 hour-30-PATCH, TRANSDERMAL 24 HOURS	01/01/2019	53.43	615.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456046101	ARMOUR THYROID-120 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	13.33	153.62	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456045701	ARMOUR THYROID-15 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	5.57	64.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456045801	ARMOUR THYROID-30 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	6.54	75.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456045901	ARMOUR THYROID-60 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	7.27	83.79	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456046001	ARMOUR THYROID-90 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	11.39	131.27	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430078327	ASACOL HD-800 mg-180-CAPSULE,DELAYED RELEASE	01/01/2019	146.84	1692.50	11/15/2021	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023590118	ASACOL HD-800 mg-180-TABLET, DELAYED RELEASE (ENTERIC COATED)	01/01/2019	146.84	1692.50	11/15/2021	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430097903	ATELVIA-35 mg-4-CAPSULE,DELAYED RELEASE	01/01/2019	12.45	266.56	01/09/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456270001	AVYCAZ-2.5 gram-1-CAPSULE,DELAYED RELEASE	01/01/2019	31.13	358.81	06/15/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456270010	AVYCAZ-2.5 gram-1-CAPSULE,DELAYED RELEASE	01/01/2019	311.30	3588.09	06/15/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914008052	BENTYL-10 mg/mL-2-CAPSULE,DELAYED RELEASE	01/01/2019	19.63	420.29	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023031304	BLEPHAMIDE S.O.P.-10 %-0.2 %-3.5-OINTMENT (GRAM)	01/01/2019	6.80	145.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980002210	BLEPHAMIDE-10 %-0.2 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	13.59	290.98	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980002205	BLEPHAMIDE-10 %-0.2 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	6.80	145.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456141030	BYSTOLIC-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.43	143.24	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456141090	BYSTOLIC-10 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	37.28	429.71	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456140263	BYSTOLIC-2.5 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	42.21	486.53	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456140230	BYSTOLIC-2.5 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.43	143.24	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456142030	BYSTOLIC-20 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.43	143.24	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456142090	BYSTOLIC-20 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	37.28	429.71	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456140563	BYSTOLIC-5 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	42.21	486.53	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456140530	BYSTOLIC-5 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.43	143.24	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456140590	BYSTOLIC-5 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	37.28	429.71	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914050156	CANASA-1,000 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	100.79	1161.78	06/06/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914050142	CANASA-1,000 mg-42-CAPSULE,DELAYED RELEASE	01/01/2019	141.11	1626.51	06/06/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914017014	CARAFATE-1 gram/10 mL-420-CAPSULE,DELAYED RELEASE	01/01/2019	18.16	209.28	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914017110	CARAFATE-1 gram-100-CAPSULE,DELAYED RELEASE	01/01/2019	33.71	388.51	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456401001	CELEXA-10 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	42.40	907.71	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456402001	CELEXA-20 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	44.19	946.10	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456404001	CELEXA-40 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	46.12	987.29	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023921110	COMBIGAN-0.2 %-0.5 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	30.60	352.68	04/19/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023921115	COMBIGAN-0.2 %-0.5 %-15-CAPSULE,DELAYED RELEASE	01/01/2019	45.89	528.98	04/19/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023921105	COMBIGAN-0.2 %-0.5 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	15.30	176.33	04/19/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611803	CONDYLOX-0.5 %-3.5-CAPSULE,DELAYED RELEASE	01/01/2019	29.58	633.34	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544025524	CRINONE-4 %-1.125-CAPSULE,DELAYED RELEASE	01/01/2019	5.02	107.52	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023615108	CRINONE-8 %-1.125-CAPSULE,DELAYED RELEASE	01/01/2019	20.94	448.20	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544025612	CRINONE-8 %-1.125-CAPSULE,DELAYED RELEASE	01/01/2019	20.94	448.20	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023585318	DELZICOL-400 mg-180-CAPSULE (WITH DELAYED RELEASE TABLETS)	01/01/2019	60.58	698.31	04/13/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430375414	ESTRACE-0.01 %-42.5-CAPSULE,DELAYED RELEASE	01/01/2019	29.91	344.78	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430072024	ESTRACE-0.5 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	25.46	545.10	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430072124	ESTRACE-1 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	25.46	545.10	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430072224	ESTRACE-2 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	32.68	699.69	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456221230	FETZIMA-120 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	34.08	392.80	05/23/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456220228	FETZIMA-20 mg (2)-40 mg (26)-28-CAPSULE,DELAYED RELEASE	01/01/2019	31.81	366.62	05/23/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456222030	FETZIMA-20 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	34.08	392.80	05/23/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456224030	FETZIMA-40 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	34.08	392.80	05/23/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456228030	FETZIMA-80 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	34.08	392.80	05/23/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544095601	FIORINAL WITH CODEINE #3-30 mg-50 mg-325 mg-40 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	52.97	1133.91	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544095501	FIORINAL-50 mg-325 mg-40 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	25.27	541.03	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980022810	FML FORTE-0.25 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	14.27	305.53	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980022805	FML FORTE-0.25 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	7.14	152.76	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023031604	FML S.O.P.-0.1 %-3.5-OINTMENT (GRAM)	01/01/2019	7.14	152.76	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980021110	FML-0.1 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	14.27	305.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980021105	FML-0.1 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	7.14	152.76	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544008430	GELNIQUE-10 % (100 mg/gram)-1-CAPSULE,DELAYED RELEASE	01/01/2019	18.48	395.53	03/26/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023586111	GELNIQUE-10 % (100 mg/gram)-1-GEL IN PACKET (GRAM)	01/01/2019	18.48	395.53	03/26/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023581230	GELNIQUE-100 mg/gram per actuation (10 %)-30-GEL IN METERED-DOSE PUMP	01/01/2019	18.48	395.53	03/26/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544020431	GENERESS FE-0.8 mg-25 mcg (24)/75 mg (~24.7 mg iron)(4)-28-CAPSULE,DELAYED RELEASE	01/01/2019	22.93	490.85	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023429003	LASTACAFT-0.25 %-3-DROPS	01/01/2019	10.53	225.39	12/23/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456201001	LEXAPRO-10 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	99.54	1147.35	02/12/2023	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456202001	LEXAPRO-20 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	103.87	1197.27	02/12/2023	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456200501	LEXAPRO-5 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	95.21	1097.38	02/12/2023	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544003554	LILETTA-19.5 mcg/24 hour (5 years) 52 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	65.02	749.40	03/22/2034	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023585801	LILETTA-19.5 mcg/24 hour (5 years) 52 mg-1-INTRAUTERINE DEVICE	01/01/2019	65.02	749.40	03/22/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456120130	LINZESS-145 mcg-30-CAPSULE,DELAYED RELEASE	01/01/2019	36.77	423.83	08/16/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456120230	LINZESS-290 mcg-30-CAPSULE,DELAYED RELEASE	01/01/2019	36.77	423.83	08/16/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456120330	LINZESS-72 mcg-30-CAPSULE,DELAYED RELEASE	01/01/2019	36.77	423.83	08/16/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430042014	LO LOESTRIN FE-1 mg-10 mcg (24)/10 mcg (2)/75 mg (2)-28-CAPSULE,DELAYED RELEASE	01/01/2019	61.04	703.59	02/02/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023320503	LUMIGAN-0.01 %-2.5-DROPS	01/01/2019	17.09	196.97	03/16/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023320505	LUMIGAN-0.01 %-5-DROPS	01/01/2019	34.16	393.78	03/16/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023320508	LUMIGAN-0.01 %-7.5-DROPS	01/01/2019	51.24	590.64	03/16/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430054050	MINASTRIN 24 FE-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE,DELAYED RELEASE	01/01/2019	41.49	888.13	04/06/2019	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456430001	MONUROL-3 gram-1-CAPSULE,DELAYED RELEASE	01/01/2019	7.54	86.92	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456341433	NAMENDA XR-14 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.32	464.77	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456341490	NAMENDA XR-14 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	120.97	1394.32	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456342133	NAMENDA XR-21 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.32	464.77	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456342833	NAMENDA XR-28 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.32	464.77	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456342890	NAMENDA XR-28 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	120.97	1394.32	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456340029	NAMENDA XR-7 mg (7)-14 mg (7)-21 mg (7)-28 mg (7)-28-CAPSULE,DELAYED RELEASE	01/01/2019	37.64	433.80	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456340733	NAMENDA XR-7 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.32	464.77	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456121430	NAMZARIC-14 mg-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.14	462.66	12/05/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456122130	NAMZARIC-21 mg-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.14	462.66	12/05/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456122830	NAMZARIC-28 mg-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.14	462.66	12/05/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456122929	NAMZARIC-7 mg-10 mg (7)/14 mg-10 mg (7)/21 mg-10 mg(7)/28 mg-10 mg(7)-28-CAPSULE,DELAYED RELEASE	01/01/2019	37.46	431.81	12/05/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456120730	NAMZARIC-7 mg-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.14	462.66	12/05/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023615301	OXYTROL-3.9 mg/24 hour-1-CAPSULE,DELAYED RELEASE	01/01/2019	3.97	84.98	04/26/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544092054	OXYTROL-3.9 mg/24 hour-1-CAPSULE,DELAYED RELEASE	01/01/2019	3.97	84.98	04/26/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023615308	OXYTROL-3.9 mg/24 hour-8-CAPSULE,DELAYED RELEASE	01/01/2019	31.76	679.85	04/26/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544092008	OXYTROL-3.9 mg/24 hour-8-CAPSULE,DELAYED RELEASE	01/01/2019	31.76	679.85	04/26/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980018010	PRED FORTE-1 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	13.59	290.98	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980018015	PRED FORTE-1 %-15-CAPSULE,DELAYED RELEASE	01/01/2019	20.39	436.47	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980018005	PRED FORTE-1 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	6.80	145.49	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980017410	PRED MILD-0.12 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	13.59	290.98	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980017405	PRED MILD-0.12 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	6.80	145.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023006604	PRED-G-0.3 %-0.6 %-3.5-OINTMENT (GRAM)	01/01/2019	6.80	145.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023010605	PRED-G-0.3 %-1 %-5-SUSPENSION, DROPS(FINAL DOSAGE FORM)(ML)	01/01/2019	6.80	145.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914060120	PYLERA-140 mg-125 mg-125 mg-120-CAPSULE,DELAYED RELEASE	01/01/2019	43.05	921.54	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023614730	RAPAFLO-4 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.21	261.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544015130	RAPAFLO-4 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.21	261.48	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023614230	RAPAFLO-8 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.21	261.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544015230	RAPAFLO-8 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.21	261.48	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023614290	RAPAFLO-8 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	36.64	784.40	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544015219	RAPAFLO-8 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	36.64	784.40	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914030180	RECTIV-0.4 % (w/w)-30-CAPSULE,DELAYED RELEASE	01/01/2019	29.93	640.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023530105	RESTASIS MULTIDOSE-0.05 %-5.5-DROPS	01/01/2019	48.39	557.72	05/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023916330	RESTASIS-0.05 %-30-CAPSULE,DELAYED RELEASE	01/01/2019	24.19	278.85	08/27/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023916360	RESTASIS-0.05 %-60-CAPSULE,DELAYED RELEASE	01/01/2019	48.39	557.72	08/27/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430021014	SARAFEM-10 mg-28-CAPSULE,DELAYED RELEASE	01/01/2019	27.31	584.74	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430022014	SARAFEM-20 mg-28-CAPSULE,DELAYED RELEASE	01/01/2019	27.31	584.74	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456151060	SAVELLA-100 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	33.14	381.93	09/19/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456150055	SAVELLA-12.5 mg (5)-25 mg (8)-50 mg (42)-55-CAPSULE,DELAYED RELEASE	01/01/2019	30.37	350.10	09/19/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456151260	SAVELLA-12.5 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	33.14	381.93	09/19/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456152560	SAVELLA-25 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	33.14	381.93	09/19/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456155060	SAVELLA-50 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	33.14	381.93	09/19/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023586230	TAYTULLA-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE	01/01/2019	81.10	934.74	03/29/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456040001	TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	16.67	192.12	02/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456040010	TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	166.68	1921.21	02/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456060001	TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	16.67	192.12	02/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456060010	TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	166.68	1921.21	02/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914079010	URSO FORTE-500 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	45.59	975.95	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914078510	URSO-250 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	25.73	550.74	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	61874010060	VIBERZI-100 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	108.85	1254.66	03/25/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	61874007560	VIBERZI-75 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	108.85	1254.66	03/25/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456110130	VIIBRYD-10 mg (7)-20 mg (23)-30-CAPSULE,DELAYED RELEASE	01/01/2019	23.62	272.24	06/05/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456111030	VIIBRYD-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	23.62	272.24	06/05/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456112030	VIIBRYD-20 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	23.62	272.24	06/05/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456114030	VIIBRYD-40 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	23.62	272.24	06/05/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611001	ZENPEP-10,000 unit-32,000 unit-42,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	29.07	335.02	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030602	ZENPEP-10,000 unit-34,000 unit-55,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	29.07	335.02	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611101	ZENPEP-15,000 unit-47,000 unit-63,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	41.98	483.87	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030202	ZENPEP-15,000 unit-51,000 unit-82,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	41.98	483.87	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611201	ZENPEP-20,000 unit-63,000 unit-84,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	57.02	657.27	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030302	ZENPEP-20,000 unit-68,000 unit-109,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	57.02	657.27	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611601	ZENPEP-25,000 unit-79,000 unit-105,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	70.56	813.34	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030502	ZENPEP-25,000 unit-85,000 unit-136,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	70.56	813.34	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611301	ZENPEP-3,000 unit-10,000 unit-14,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	15.41	177.63	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030402	ZENPEP-3,000 unit-10,000 unit-16,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	15.41	177.63	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611401	ZENPEP-40,000 unit-126,000 unit-168,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	112.54	1297.15	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030702	ZENPEP-40,000 unit-136,000 unit-218,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	112.54	1297.15	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611501	ZENPEP-5,000 unit-17,000 unit-24,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	14.70	169.48	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030002	ZENPEP-5,000 unit-17,000 unit-27,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	14.70	169.48	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000037	AMAG Pharmaceuticals, Inc.	03/31/2019	59338077501	ferumoxytol 510MG/17 mL Feraheme 510mg Each	01/01/2019	27.46	942.79	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	06/30/2019	59338077501	ferumoxytol 510MG/17 mL Feraheme 510mg Each	04/01/2019	28.28	971.07	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	09/30/2019	59338077501	ferumoxytol 510MG/17 mL Feraheme 510mg Each	07/01/2019	29.13	1000.20	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. As a result of these efforts, AMAG received FDA approval for an expanded label for Feraheme in February 2018 to allow treatment of all eligible adults with iron deficiency anemia. This sNDA approval doubles the number of patients who could benefit from Feraheme to include both CKD and non-CKD patients
Rx0000037	AMAG Pharmaceuticals, Inc.	12/31/2019	59338077501	ferumoxytol 510MG/17 mL Feraheme 510mg Each	10/01/2019	30.01	1030.21	06/30/2023	Single Source Drug	None	1	Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	03/31/2019	59338077510	ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10	01/01/2019	274.60	9427.90	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	06/30/2019	59338077510	ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10	04/01/2019	282.80	9710.70	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	09/30/2019	59338077510	ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10	07/01/2019	291.32	10002.02	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. As a result of these efforts, AMAG received FDA approval for an expanded label for Feraheme in February 2018 to allow treatment of all eligible adults with iron deficiency anemia. This sNDA approval doubles the number of patients who could benefit from Feraheme to include both CKD and non-CKD patients
Rx0000037	AMAG Pharmaceuticals, Inc.	12/31/2019	59338077510	ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10	10/01/2019	300.06	10302.08	06/30/2023	Single Source Drug	None	1	Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000050	Amarin Pharma, Inc.	12/31/2019	52937000120	Vascepa(Icosapent ethyl) 120 1g	12/31/2019	27.33	330.98	06/28/2033	Single Source Drug	3158163	None	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=336	VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride (TG) levels, developed, and manufactured by Amarin Pharmaceuticals.
Rx0000050	Amarin Pharma, Inc.	12/31/2019	52937000340	Vascepa(Icosapent ethyl) 240 500 mg	12/31/2019	31.97	387.24	06/28/2033	Single Source Drug	34858	None	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=337	VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride (TG) levels, developed, and manufactured by Amarin Pharmaceuticals.
Rx0000231	American Health Packaging	12/31/2019	68084037301	Acetaminophen & Codeine Phosphate Tablet CIII 300mg/60mg 100UD	12/13/2019	33.79	92.50	None	Non-innovator Multiple Source Drug	3545	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084077725	Acetaminophen ER Tablet 650mg 30UD	12/05/2019	6.45	25.13	None	Non-innovator Multiple Source Drug	3382	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084010701	Acyclovir Capsule 200mg 100UD	12/13/2019	4.67	34.08	None	Non-innovator Multiple Source Drug	6413	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	60687028621	Bromocriptine Mesylate Tablet 2.5mg 30UD	03/27/2019	59.82	206.88	None	Non-innovator Multiple Source Drug	3081	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084028101	Carbidopa & Levodopa ER Tablet 25mg/100mg 100UD	12/05/2019	47.29	78.44	None	Non-innovator Multiple Source Drug	8151	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084024401	Clindamycin HCl Capsule 300mg 100UD	08/01/2019	19.71	110.58	None	Non-innovator Multiple Source Drug	4662	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	60687042321	Clobazam Tablet CIV 10mg 30UD	12/05/2019	11.25	65.00	None	Non-innovator Multiple Source Drug	0	1	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	60687035825	Colchicine Capsule 0.6mg 30UD	11/08/2019	37.12	204.00	None	Non-innovator Multiple Source Drug	3321	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084060621	Desmopressin Acetate Tablet 0.1mg 30UD	11/08/2019	13.06	56.98	None	Non-innovator Multiple Source Drug	5246	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084033301	Diclofenac Sodium DR Tablet 75mg 100UD	12/05/2019	13.55	67.05	None	Non-innovator Multiple Source Drug	1259	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	60687036901	Dicyclomine HCl Capsule 10mg 100UD	09/27/2019	9.57	54.94	None	Non-innovator Multiple Source Drug	1743	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	60687022801	Diltiazem HCI Capsule ER 24h 300mg 100UD	09/12/2019	29.58	158.99	None	Non-innovator Multiple Source Drug	2204	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68084074332	Doxycycline Capsule 100mg 20UD	03/05/2019	8.63	29.81	None	Non-innovator Multiple Source Drug	14708	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084032921	Fenofibrate Capsule 200mg 30UD	12/05/2019	35.23	150.00	None	Non-innovator Multiple Source Drug	1761	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68084028801	Fludrocortisone Acetate Tablet 0.1mg 100UD	03/05/2019	14.16	84.38	None	Non-innovator Multiple Source Drug	16476	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084072921	Galantamine Tablet 4mg 30UD	08/01/2019	44.47	105.00	None	Non-innovator Multiple Source Drug	1695	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084011201	Glipizide ER Tablet 10mg 100UD	12/05/2019	15.50	88.44	None	Non-innovator Multiple Source Drug	2238	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2019	68084029521	Glipizide ER Tablet 2.5mg 30UD	05/13/2019	4.25	34.00	None	Non-innovator Multiple Source Drug	0	1	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	Price increase >16% when factoring previous two years of price changes. The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68084074825	Guanfacine Tablet 1mg 30UD	03/05/2019	22.21	46.90	None	Non-innovator Multiple Source Drug	8106	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2019	68084025021	Haloperidol Tablet 20mg 30UD	05/23/2019	34.28	139.81	None	Non-innovator Multiple Source Drug	4597	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2019	60687016101	Haloperidol Tablet 5mg 100UD	05/29/2019	26.29	91.00	None	Non-innovator Multiple Source Drug	12693	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084084701	Hydroxyzine Pamoate Capsule 25mg 100UD	09/27/2019	25.32	50.00	None	Non-innovator Multiple Source Drug	24756	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68001037400	ISOSORBIDE DINITRATE TAB 10MG 100	03/28/2019	28.89	86.68	None	Non-innovator Multiple Source Drug	0	1	Market Conditions	None	No change or improvement in the drug product	None	02/27/2019	Blue Point Laboratories	350955	None	BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product.	57.79	None	2019	57.79	None	Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231	American Health Packaging	03/31/2019	68001037500	ISOSORBIDE DINITRATE TAB 20MG 100	03/28/2019	31.78	95.35	None	Non-innovator Multiple Source Drug	0	1	Market Conditions	None	No change or improvement in the drug product	None	02/27/2019	Blue Point Laboratories	448145	None	BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product.	63.57	None	2019	63.57	None	Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231	American Health Packaging	03/31/2019	68001033708	LISINOPRIL TAB 40 MG 1000	02/11/2019	47.30	116.36	None	Non-innovator Multiple Source Drug	22870	None	Market Conditions	None	No change or improvement in the drug product	None	03/18/2019	Blue Point Laboratories	207786	None	BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product.	116.36	None	2017	116.36	None	Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231	American Health Packaging	03/31/2019	68001033308	LISINOPRIL TAB 5 MG 1000	02/11/2019	6.80	37.41	None	Non-innovator Multiple Source Drug	22686	None	Market Conditions	None	No change or improvement in the drug product	None	03/15/2019	Blue Point Laboratories	245872	None	BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product.	30.61	None	2017	30.61	None	Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231	American Health Packaging	12/31/2019	68084073801	Methadone HCl Tablet CII 10mg 100UD	12/05/2019	4.38	30.26	None	Non-innovator Multiple Source Drug	14073	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	60687035701	Methimazole Tablet 5mg 100UD	09/04/2019	13.35	50.00	None	Non-innovator Multiple Source Drug	700	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084067601	Metoclopramide Tablet 10mg 100UD	09/04/2019	19.00	40.00	None	Non-innovator Multiple Source Drug	13788	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084004001	Misoprostol Tablet 100mcg 100UD	12/05/2019	70.33	206.58	None	Non-innovator Multiple Source Drug	7108	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084004101	Misoprostol Tablet 200mcg 100UD	12/05/2019	67.14	227.14	None	Non-innovator Multiple Source Drug	15565	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	60687037401	Nabumetone Tablet 500mg 100UD	02/18/2019	39.11	105.00	None	Non-innovator Multiple Source Drug	0	1	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68001031800	NADOLOL TAB 40MG 100	03/28/2019	103.06	320.94	None	Non-innovator Multiple Source Drug	2062	None	Market Conditions	None	No change or improvement in the drug product	None	02/04/2019	Blue Point Laboratories	444930	None	BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product.	320.94	None	2017	320.94	None	Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231	American Health Packaging	03/31/2019	68084059701	Nifedipine ER Tablet 30mg 100UD	03/14/2019	47.84	149.00	None	Non-innovator Multiple Source Drug	14896	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68084059801	Nifedipine ER Tablet 60mg 100UD	03/14/2019	72.83	247.25	None	Non-innovator Multiple Source Drug	5829	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68084060321	Nifedipine ER Tablet 90mg 30UD	03/14/2019	35.69	93.63	None	Non-innovator Multiple Source Drug	8873	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	62584081201	Oxazepam Capsule CIV 10mg 100UD	12/05/2019	42.50	198.75	None	Non-innovator Multiple Source Drug	2113	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	62584081301	Oxazepam Capsule CIV 15mg 100UD	12/05/2019	37.48	218.73	None	Non-innovator Multiple Source Drug	4681	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	62584081401	Oxazepam Capsule CIV 30mg 100UD	12/05/2019	64.18	242.80	None	Non-innovator Multiple Source Drug	1104	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084084501	Oxcarbazepine Tablet 150mg 100UD	09/04/2019	21.54	53.85	None	Non-innovator Multiple Source Drug	9550	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084085301	Oxcarbazepine Tablet 300mg 100UD	09/04/2019	26.62	88.31	None	Non-innovator Multiple Source Drug	16133	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084086701	Oxcarbazepine Tablet 600mg 100UD	09/04/2019	46.61	155.07	None	Non-innovator Multiple Source Drug	6626	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084004601	Paroxetine HCl Tablet 30mg 100UD	12/13/2019	14.82	94.82	None	Non-innovator Multiple Source Drug	783	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084063201	Potassium Chloride ER Tablet 10mEq K 100UD	12/05/2019	25.71	73.21	None	Non-innovator Multiple Source Drug	21782	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084096425	Propylthiouracil Tablet 50mg 30UD	12/05/2019	19.00	84.00	None	Non-innovator Multiple Source Drug	4089	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	60687023101	Sertraline Tablet 25mg 100UD	09/04/2019	11.23	37.43	None	Non-innovator Multiple Source Drug	20735	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	60687024201	Sertraline Tablet 50mg 100UD	09/04/2019	12.52	39.19	None	Non-innovator Multiple Source Drug	91066	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084034401	Topiramate Tablet 100mg 100UD	08/01/2019	22.46	47.46	None	Non-innovator Multiple Source Drug	22870	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084034201	Topiramate Tablet 25mg 100UD	08/01/2019	12.76	29.76	None	Non-innovator Multiple Source Drug	32279	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000128	American Regent	09/30/2019	00517065001	Ferric Carboxymaltose 750 MG/15ML Solution 15 ML UD	07/01/2019	31.29	1074.25	02/15/2028	Single Source Drug	183439	None	American Regent’s US Standards of Business Conduct (available at https://dsi.com/documents/376460/376852/DSI_SOBC.pdf/248ffd7a-3614-e6cc-bf02-4dd99641a79b) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition	None	None	1	None	None	None	None	None	None	None	None	None	None	Injectafer is not an acquired product. American Regent is the NDA holder of this NDC.
Rx0000069	Amgen	03/31/2019	58406042541	''ENBREL 25 mg (1mL) VIAL (EA), 1 pk''	01/17/2019	37.76	646.76	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406042534	''ENBREL 25 mg (1mL) VIAL (EA), 4 pk''	01/17/2019	151.03	2587.03	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406045501	''ENBREL 25 mg/0.5mL (0.51mL) SYRINGE (mL), 1 pk''	01/17/2019	37.76	646.76	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406045504	''ENBREL 25 mg/0.5mL (0.51mL) SYRINGE (mL), 4 pk''	01/17/2019	151.03	2587.03	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406043501	''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 1 pk''	01/17/2019	75.52	1293.52	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406044501	''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 1 pk''	01/17/2019	75.52	1293.52	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406043504	''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 4 pk''	01/17/2019	302.06	5174.06	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406044504	''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 4 pk''	01/17/2019	302.06	5174.06	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	76075010201	''KYPROLIS 30 mg (2 mg/mL) VIAL (EA), 1 pk''	01/17/2019	33.81	1160.83	12/07/2027	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	76075010101	''KYPROLIS 60 mg VIAL (EA), 1 pk''	01/17/2019	67.62	2321.66	12/07/2027	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	55513022101	''NPLATE 250 mcg (0.5mL) VIAL (EA), 1 pk''	01/17/2019	54.13	1858.58	01/19/2022	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	55513022201	''NPLATE 500 mcg (1.0mL) VIAL (EA), 1 pk''	01/17/2019	108.26	3717.16	01/19/2022	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Amgen
Rx0000069	Amgen	03/31/2019	55513071001	''PROLIA 60 mg (1.0mL) SYRINGE (mL), 1 pk''	01/17/2019	35.51	1219.06	02/19/2025	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Amgen
Rx0000122	Amneal Pharmaceuticals	03/31/2019	53746066901	Acebutolol HCl Oral Capsule 200 MG 100	02/06/2019	40.90	65.00	None	Non-innovator Multiple Source Drug	105216	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	65162066910	Acebutolol HCl Oral Capsule 200 MG 100	01/25/2019	40.90	65.00	None	Non-innovator Multiple Source Drug	11383	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	53746067001	Acebutolol HCl Oral Capsule 400 MG 100	02/06/2019	55.82	86.00	None	Innovator Multiple Source Drug	20151	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	65162067010	Acebutolol HCl Oral Capsule 400 MG 100	01/25/2019	55.82	86.00	None	Innovator Multiple Source Drug	11172	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846020101	Activella (estradiol/norethindrone acetate) Tablets 0.5mg/.01mg 1 Dial x 28 tabs	01/04/2019	23.03	255.61	None	Innovator Multiple Source Drug	8952	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846020201	Activella (estradiol/norethindrone acetate) Tablets 1.0mg/.05mg 1 Dial x 28 tabs	01/04/2019	25.31	280.95	None	Innovator Multiple Source Drug	7957	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	52054055022	Albenza Oral Tablet 200 MG 2Tabs	01/04/2019	43.72	485.34	None	Innovator Multiple Source Drug	316688	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	52054051309	Dexedrine Oral Capsule Extended Release 24 Hour 10 MG 90 caps	01/04/2019	190.05	2109.72	None	Innovator Multiple Source Drug	2649	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	52054051409	Dexedrine Oral Capsule Extended Release 24 Hour 15 MG 90 caps	01/04/2019	190.05	2109.72	None	Innovator Multiple Source Drug	4223	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	52054051209	Dexedrine Oral Capsule Extended Release 24 Hour 5 MG 90 caps	01/04/2019	190.05	2109.72	None	Innovator Multiple Source Drug	515	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	65162071110	Guanfacine HCl Oral Tablet 1 MG 100	02/06/2019	35.60	56.00	None	Innovator Multiple Source Drug	372489	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	65162071310	Guanfacine HCl Oral Tablet 2 MG 100	02/06/2019	58.40	87.00	None	Non-innovator Multiple Source Drug	109752	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	53746046605	Ibuprofen Oral Tablet 800 MG 500	03/28/2019	11.75	80.25	None	Non-innovator Multiple Source Drug	194	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	65162046650	Ibuprofen Oral Tablet 800 MG 500	03/28/2019	11.75	80.25	None	Non-innovator Multiple Source Drug	237540	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846030115	Nizatidine Oral Solution 15mg/mL 480 Bottle	01/04/2019	45.65	506.78	None	Non-innovator Multiple Source Drug	7206	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846088201	Prandin® (repaglinide tablets) 1mg 100 Tabs	01/04/2019	71.40	792.64	None	Non-innovator Multiple Source Drug	5667	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	05/07/2018	Gemini Laboratories, LLC	None	None	Amneal does not have the ability to separate the portion of the total acquisition price allocated to the individual drug products. Total amount was 117000000	656.26	625.61	2013	339.25	None	Column 12 Blank - No change to the product
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846088401	Prandin® (repaglinide tablets) 2mg 100 Tab	01/04/2019	71.40	792.64	None	Non-innovator Multiple Source Drug	9733	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	05/07/2018	Gemini Laboratories, LLC	None	None	Amneal does not have the ability to separate the portion of the total acquisition price allocated to the individual drug products. Total amount was 117000000	656.26	625.61	2013	339.25	None	Column 12 Blank - No change to the product
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846050101	Pyridium® (phenazopyridine HCL) 100mg 100 Tab	01/04/2019	71.40	443.43	None	Non-innovator Multiple Source Drug	2557	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846050201	Pyridium® (phenazopyridine HCL) 200mg 100 Tab	01/04/2019	51.36	570.13	None	Non-innovator Multiple Source Drug	3459	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	64896066101	Rytary 23.75mg/95mg ER Cap 100ct	01/04/2019	28.88	320.56	12/26/2028	Single Source Drug	206350	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	64896066201	Rytary 36.25mg/145mg ER Cap 100ct	01/04/2019	28.88	320.56	12/26/2028	Single Source Drug	205662	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	64896066301	Rytary 48.75mg/195mg ER Cap 100ct	01/04/2019	28.88	320.56	12/26/2028	Single Source Drug	233657	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	64896066401	Rytary 61.25mg/245mg ER Cap 100ct	01/04/2019	36.28	402.79	12/26/2028	Single Source Drug	100797	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	06/30/2019	65162055650	Temazepam Oral Capsule 15 MG 500	05/08/2019	37.30	64.30	None	Non-innovator Multiple Source Drug	0	1	Manufacturing costs and market conditions require increase to remain on market	None	No change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired from another company. No changes were made to the product .This was a relaunch so there was no unit sales volume during this time frame.
Rx0000122	Amneal Pharmaceuticals	06/30/2019	65162055750	Temazepam Oral Capsule 30 MG 500	05/08/2019	42.25	76.90	None	Non-innovator Multiple Source Drug	0	1	Manufacturing costs and market conditions require increase to remain on market	None	No change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired from another company. No changes were made to the product. This was a relaunch so there was no unit sales volume during this time frame.
Rx0000271	Apotex Corp	06/30/2019	60505058204	MOXIFLOXACIN HCL OP/SLN 0.5% 3ML	04/11/2019	33.47	66.94	None	Non-innovator Multiple Source Drug	2099287	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	12/31/2019	53451010301	HORIZANT Oral Tablet Extended Release 300 MG, 30 tablets in a bottle	10/01/2019	23.31	411.84	06/10/2029	Single Source Drug	59056	None	Increases in rate of inflation, continued investment in innvotion, post-marketing regulatory commitments and requiremens, ongoing pharmacovigilance, market conditions and dynamics	None	None	1	07/05/2016	Xenoport, Inc.	467000000	None	Price was for both product strengths and additional IP and assets	330.40	280.00	2014	162.07	None	All information is provided by Arbor to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Arbor provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Arbor does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Arbor or any of its affiliates now or in the future. Arbor, on behalf of itself and affiliates, expressly reserves all such rights. Arbor believes that this submission and of all Arbor related information set forth in this submission is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Arbor’s related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Arbor is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000132	Arbor Pharmaceuticals, LLC	12/31/2019	53451010101	HORIZANT Oral Tablet Extended Release 600 MG, 30 tablets in a bottle	10/01/2019	23.31	411.84	06/10/2029	Single Source Drug	215303	None	Increases in rate of inflation, continued investment in innvotion, post-marketing regulatory commitments and requiremens, ongoing pharmacovigilance, market conditions and dynamics	None	None	1	07/05/2016	Xenoport, Inc.	467000000	None	Price was for both product strengths and additional IP and assets	330.40	280.00	2011	99.00	None	All information is provided by Arbor to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Pricing for 2011 is based on information that Arbor obtained in conjunction with the acquisition of Horizant based on publicly available information available at the time. That information is no longer available and Arbor is relying on its records from that time in making this submission. Arbor provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Arbor does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Arbor or any of its affiliates now or in the future. Arbor, on behalf of itself and affiliates, expressly reserves all such rights. Arbor believes that this submission and of all Arbor related information set forth in this submission is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Arbor’s related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Arbor is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000274	Artesa Labs, LLC	12/31/2019	57883040105	Keralac Cream, (urea 47%), Cream, 142 g	12/19/2019	40.03	693.00	None	Innovator Multiple Source Drug	4098	None	Raw materials, regulations	None	None	1	08/01/2017	Mission Pharmacal Company	None	1	None	594.15	None	2014	395.00	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893031210	MimyX Cream, n/a, Cream, 100 g	12/19/2019	30.00	520.00	None	Single Source Drug	8772	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893031060	Nolix Cream, (flurandrenolide 0.05%), Cream, 120 g	12/19/2019	54.82	956.00	None	Non-innovator Multiple Source Drug	2070	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893031112	Nolix Lotion, (flurandrenolide 0.05%), Lotion, 120 mL	12/19/2019	42.12	729.00	None	Non-innovator Multiple Source Drug	3342	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57883040210	Plexion Cleanser, (sodium sulfacetamide 9.8%, sulfur 4.8%), Cleanser, 285 g	12/19/2019	40.03	693.00	None	Innovator Multiple Source Drug	65946	None	Raw materials, regulations	None	None	1	08/01/2017	Mission Pharmacal Company	None	1	None	594.15	None	2014	395.00	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57883040460	Plexion Cleansing Cloths, (sodium sulfacetamide 9.8%, sulfur 4.8%), Cloths, 60 ct. (4 g each)	12/19/2019	42.82	752.00	None	Single Source Drug	5964	None	Raw materials, regulations	None	None	1	08/01/2017	Mission Pharmacal Company	None	1	None	645.30	None	2014	395.00	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57883040302	Plexion Cream, (sodium sulfacetamide 9.8%, sulfur 4.8%), Cream, 57 g	12/19/2019	36.33	641.00	None	Innovator Multiple Source Drug	8168	None	Raw materials, regulations	None	None	1	08/01/2017	Mission Pharmacal Company	None	1	None	550.20	None	2014	435.00	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57883040502	Plexion Lotion, (sodium sulfacetamide 9.8%, sulfur 4.8%), Lotion, 57 g	12/19/2019	39.93	699.00	None	Innovator Multiple Source Drug	6918	None	Raw materials, regulations	None	None	1	08/01/2017	Mission Pharmacal Company	None	1	None	599.70	None	2014	435.00	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893030399	Riax Foam 5.5%, (benzoyl peroxide 5.5%), Form, 100 g	12/19/2019	30.87	543.00	None	Single Source Drug	4176	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893030499	Riax Foam 9.5%, (benzoyl peroxide 9.5%), Form, 100 g	12/19/2019	30.87	543.00	None	Single Source Drug	6246	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893030006	SelRx Shampoo, (selenium sulfide 2.3%), Shampoo, 180 mL	12/19/2019	34.72	604.00	None	Innovator Multiple Source Drug	7240	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893030108	Utopic Cream, (urea 41%), Cream, 227 g	12/19/2019	49.96	883.00	None	Innovator Multiple Source Drug	7524	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893030230	Vytone Cream, (hydrocortisone acetate 1.9%, iodoquinol 1%), 30 ct. (2 g each)	12/19/2019	48.43	854.00	None	Innovator Multiple Source Drug	9636	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000147	ASCEND Therapeutics US, LLC	12/31/2019	17139040004	Binosto (alendronate sodium) Effervescent tablet for oral solution, 70mg, 4 tablets in 1 carton	11/27/2019	98.40	300.00	08/11/2023	Single Source Drug	None	1	None	1	None	1	09/15/2019	Mission Pharmacal Company	None	1	None	201.60	201.60	2012	140.00	None	None
Rx0000075	Assertio Therapeutics, Inc.	03/31/2019	13913001201	Cambia (diclofenac potassium), 50MG, Oral, 1 Packet	02/08/2019	6.81	75.62	06/16/2026	Single Source Drug	1139039	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past 5 years
Rx0000075	Assertio Therapeutics, Inc.	03/31/2019	13913000419	Gralise (gabapentin), 300MG, Oral Tablet, 90 Ct Bottle	02/08/2019	75.62	839.42	02/26/2024	Single Source Drug	1969210	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past 5 years
Rx0000075	Assertio Therapeutics, Inc.	03/31/2019	13913000519	Gralise (gabapentin), 600MG, Oral Tablet, 90 Ct Bottle	02/08/2019	75.62	839.42	02/26/2024	Single Source Drug	15463198	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past 5 years
Rx0000075	Assertio Therapeutics, Inc.	03/31/2019	13913000812	Zipsor (diclofenac potassium), 25MG, Oral Capsule, 100 Ct Bottle	02/08/2019	128.73	1429.07	02/24/2029	Single Source Drug	2365310	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past 5 years
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469032014	CRESEMBA®186mg 14 Capsules	01/08/2019	73.36	1295.91	10/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469052014	CRESEMBA®186mg 14 Capsules	01/08/2019	73.36	1295.91	10/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469042099	CRESEMBA®372mg Vial	01/08/2019	17.85	315.39	10/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260171	Myrbetriq®25mg 100 Tablet	01/08/2019	105.77	1280.98	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260130	Myrbetriq®25mg 30 Tablet	01/08/2019	31.73	384.29	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260190	Myrbetriq®25mg 90 Tablet	01/08/2019	95.19	1152.87	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260271	Myrbetriq®50mg 100 Tablet	01/08/2019	105.77	1280.98	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260230	Myrbetriq®50mg 30 Tablet	01/08/2019	31.73	384.29	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260290	Myrbetriq®50mg 90 Tablet	01/08/2019	95.19	1152.87	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469060773	Prograf®0.5mg 100 Capsules	01/08/2019	2.98	301.62	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469061711	Prograf®1mg 100 Capsules	01/08/2019	5.97	603.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469061773	Prograf®1mg 100 Capsules	01/08/2019	5.97	603.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469301601	Prograf®5mg 10 1ML Ampules	01/08/2019	20.58	2079.09	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469065711	Prograf®5mg 100 Capsules	01/08/2019	29.87	3016.22	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469065773	Prograf®5mg 100 Capsules	01/08/2019	29.87	3016.22	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015152	VESIcare®10mg 100 Tablet	01/08/2019	72.73	1285.03	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015101	VESIcare®10mg 30 Tablet	01/08/2019	21.82	385.51	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015103	VESIcare®10mg 90 Tablet	01/08/2019	65.46	1156.53	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015052	VESIcare®5mg 100 Tablet	01/08/2019	72.73	1285.03	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015001	VESIcare®5mg 30 Tablet	01/08/2019	21.82	385.51	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015003	VESIcare®5mg 90 Tablet	01/08/2019	65.46	1156.53	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469012599	XTANDI®40mg 120 Capsules	01/08/2019	643.41	11548.60	08/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000015	AstraZeneca	03/31/2019	00310621030	Farxiga 10mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	1289346480	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	289.20	None	2014	289.20	None	None
Rx0000015	AstraZeneca	03/31/2019	00310620530	Farxiga 5mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	599751771	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	289.20	None	2014	289.20	None	None
Rx0000015	AstraZeneca	03/31/2019	00310628030	Xigduo XR 10-1000mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	129626100	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000015	AstraZeneca	03/31/2019	00310627030	Xigduo XR 10-500mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	13322599	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000015	AstraZeneca	03/31/2019	00310626060	Xigduo XR 5-1000mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	212483946	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000015	AstraZeneca	03/31/2019	00310625030	Xigduo XR 5-500mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	22269231	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000058	Avanir Pharmaceuiticals	06/30/2019	64597030160	NUEDEXTA (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg), Bottles of 60 capsules	05/01/2019	76.00	1174.00	08/13/2026	Single Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	NOTE: columns 14-22 are intentionally blank since our product does not meet the requirements for completing these columns.
Rx0000108	AvKare	12/31/2019	50268068515	Prochlorperazine Maleate 10 MG Tablet 50 EA UD	10/29/2019	30.22	73.93	None	Non-innovator Multiple Source Drug	1578	None	Increase in Cost of Goods	None	There was no significant changes or improvements to this drug	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired
Rx0000108	AvKare	12/31/2019	50268068415	Prochlorperazine Maleate 5 MG Tablet 50 EA UD	10/29/2019	25.90	67.14	None	Non-innovator Multiple Source Drug	1236	None	Increase in Cost of Goods	None	There was no significant changes or improvements to this drug	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired